Searching…
Jun 15, 2015 · Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer
Dec 1, 1999 · Phase III study of doxorubcin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results ...
A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High Risk Node-Negative Breast Cancer (CALGB 49906...
Feb 25, 2006 · 作为紫杉类的另一种代表药物多西他赛,在乳腺癌的辅助治疗中也得到了广泛应用,但泰素和多西他赛辅助治疗乳腺癌孰优孰劣一直存有争议。 E1199试验是第一项在序贯方案中直接比较泰素和多西他赛辅助治疗乳腺癌的研究,对临床选择用药有一定的指导意义。
美国东部肿瘤合作组 (ECOG)开展的E1199试验证实，紫杉类药物是治疗乳腺癌的重要药物。 该试验既往的研究结果确立了两种紫杉类药物的重要应用方案，即AC方案序贯使用紫杉类药物时，紫杉醇应采用周疗 (P1)，而多西他赛应采用3周疗法 (D3)。
Jul 7, 2015 · Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer The following represents disclosure information provided by authors of this manuscript.
Jul 20, 2015 · Improved outcomes initially observed for weekly paclitaxel were qualitatively similar but quantitatively less pronounced with longer follow-up, although exploratory analysis suggested substantial benefi...
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. Journal of Clinical Oncology, 33 (21), 2353–2360. http://doi.org/10.1200/JCO.2015.60.9271
Dive into the research topics of 'Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer'. Together they form a unique fingerprint.
May 1, 2015 · Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negat...
